Vericiguat

  • TRADE NAME: Verquvo (Merck Sharpe & Dohme)
  • INDICATIONS:

    To reduce risk of cardiovascular death and hospitalization for heart failure in chronic heart failure


  • CLASS: Guanylate cyclase stimulator
  • HALF-LIFE: 30 hours (in patients with heart failure)

FDA APPROVAL DATE: 01/19/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

PDE-5 inhibitors, Sildenafil

EMBRYO-FETAL TOXICITY: DO NOT ADMINISTER VERICIGUAT TO A PREGNANT FEMALE BECAUSE IT MAY CAUSE FETAL HARM.

FEMALES OF REPRODUCTIVE POTENTIAL: EXCLUDE PREGNANCY BEFORE THE START OF TREATMENT. TO PREVENT PREGNANCY, FEMALES OF REPRODUCTIVE POTENTIAL MUST USE EFFECTIVE FORMS OF CONTRACEPTION DURING TREATMENT AND FOR ONE MONTH AFTER STOPPING TREATMENT.


See full prescribing information for complete boxed warning

Our database has 2 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
HEMATOLOGIC.


Page last updated 10/09/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top